123 related articles for article (PubMed ID: 238221)
1. Intensification of central catecholaminergin and serotonergic processes by the hypothalamic factors MIF and TRF and by angiotensin II.
Huidobro-Toro JP; Scotti de Carolis A; Longo VG
Pharmacol Biochem Behav; 1975; 3(2):235-42. PubMed ID: 238221
[TBL] [Abstract][Full Text] [Related]
2. Action of two hypothalamic factors (TRH, MIF) and of angiotensin II on the behavioral effects of L-DOPA and 5-hydroxytryptophan in mice.
Huidobro-Toro JP; De Carolis AS; Longo VG
Pharmacol Biochem Behav; 1974; 2(1):105-9. PubMed ID: 4364044
[No Abstract] [Full Text] [Related]
3. Synthetic melanocyte stimulating hormone release-inhibiting factor (MIF). Part III: effect of L-prolyl-N-methyl-D-leucyl-glycinamide and MIF on biogenic amine turnover.
Pugsley TA; Lippmann W
Arzneimittelforschung; 1977; 27(12):2293-6. PubMed ID: 23796
[TBL] [Abstract][Full Text] [Related]
4. Synthetic MIF analogues. Part II: Dopa potentiation and fluphenazine antagonism.
Voith K
Arzneimittelforschung; 1977; 27(12):2290-3. PubMed ID: 23795
[TBL] [Abstract][Full Text] [Related]
5. Prolyl-leucyl-glycine amide (PLG) and thyrotropin-releasing hormone (TRH): DOPA potentiation and biogenic amine studies.
Plotnikoff NP
Prog Brain Res; 1975; 42():11-23. PubMed ID: 730
[No Abstract] [Full Text] [Related]
6. Central effects of thyrotropin-releasing factor (TRF); interaction with some antipsychotic drugs.
Mora S; Loizzo A; Longo VG
Pharmacol Biochem Behav; 1976 Mar; 4(3):279-82. PubMed ID: 819939
[TBL] [Abstract][Full Text] [Related]
7. Possible association of increased rat behavioral effects and increased striatal dopamine and norepinephrine levels during the DOPA-potentiation test.
Spirtes MA; Plotnikoff NP; Kostrzewa RM; Harston CT; Kastin AJ; Christensen CW
Pharmacol Biochem Behav; 1976; 5(Suppl 1):121-4. PubMed ID: 13411
[TBL] [Abstract][Full Text] [Related]
8. Thyrotropin releasing hormone (TRH): DOPA potentiation and biogenic amine studies.
Plotnikoff NP; Breese GR; Prange AJ
Pharmacol Biochem Behav; 1975; 3(4):665-70. PubMed ID: 810812
[TBL] [Abstract][Full Text] [Related]
9. MIF-1: effects on norepinephrine, dopamine and serotonin metabolism in certain discrete brain regions.
Singhal RL; Rastogi RB
Pharmacol Biochem Behav; 1982 Feb; 16(2):229-33. PubMed ID: 6122214
[TBL] [Abstract][Full Text] [Related]
10. A comparison between a melanocyte-stimulating hormone inhibitory factor (MIF-I) and substances known to activate central dopamine receptors.
Cox B; Kastin AJ; Schnieden H
Eur J Pharmacol; 1976 Mar; 36(1):141-7. PubMed ID: 4332
[TBL] [Abstract][Full Text] [Related]
11. Thyrotropin releasing hormone: enhancement of dopa activity by a hypothalamic hormone.
Plotnikoff NP; Prange AJ; Breese GR; Anderson MS; Wilson IC
Science; 1972 Oct; 178(4059):417-8. PubMed ID: 4627781
[TBL] [Abstract][Full Text] [Related]
12. Behavioral and prolactin responses to 5-hydroxytryptophan in rats treated during development with 5,7-dihydroxytryptamine.
Breese GR; Vogel RA; Kuhn CM; Mailman RB; Mueller RA; Schanberg SM
Brain Res; 1978 Oct; 155(2):263-75. PubMed ID: 308387
[TBL] [Abstract][Full Text] [Related]
13. Correlation of nitric oxide (NO) activity and gonadal function in Japanese quail, Coturnix coturnix japonica following temporal phase relation of serotonergic and dopaminergic oscillations.
Kumar P; Chaturvedi CM
Anim Reprod Sci; 2008 Jun; 106(1-2):48-64. PubMed ID: 17512145
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological characteristics of abnormal behavior induced by harmine with special reference to tremor in mice.
Kawanishi K; Hashimoto Y; Fujiwara M; Kataoka Y; Ueki S
J Pharmacobiodyn; 1981 Jul; 4(7):520-7. PubMed ID: 6975366
[TBL] [Abstract][Full Text] [Related]
15. Study of the structural requirements for dopa potentiation and oxotremorine antagonism by L-prolyl-L-leucylglycinamide.
Johnson RL; Smissman EE; Plotnikoff NP
J Med Chem; 1978 Feb; 21(2):165-9. PubMed ID: 23433
[TBL] [Abstract][Full Text] [Related]
16. Effects of the tripeptides TRH, MIF and MAF on the cerebral dopaminergic system.
Klusha B; Georgiev V; Petkov V; Markovska V
Acta Physiol Pharmacol Bulg; 1983; 9(2):14-9. PubMed ID: 6140814
[TBL] [Abstract][Full Text] [Related]
17. Behavioral effects of melanocyte stimulating hormone release-inhibiting factor-1 (MIF-1).
von Almen TK; Olson GA; Olson RD
Neurosci Biobehav Rev; 1983; 7(2):257-62. PubMed ID: 6136015
[TBL] [Abstract][Full Text] [Related]
18. The action of psychotropic drugs on DOPA induced behavioural responses in mice.
Berendsen H; Leonard BE; Rigter H
Arzneimittelforschung; 1976; 26(9):1686-9. PubMed ID: 11809
[TBL] [Abstract][Full Text] [Related]
19. Comparison of thyrotropin-releasing hormone with melanocyte-stimulating-hormone-release-inhibiting factor as pentobarbital antagonists in monkeys.
Crowley TJ; Hydinger M
Psychopharmacology (Berl); 1977 Jul; 53(2):205-6. PubMed ID: 19803
[TBL] [Abstract][Full Text] [Related]
20. Different effects of harmine on plasma concentrations of L-dopa and on cerebral dopamine metabolism in rabbits and rats.
Meneguz A; Betto P; Ricciarello G
Pharmacology; 1994 Jun; 48(6):360-6. PubMed ID: 8047555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
